These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 16551202)

  • 1. Managing the expanded use of biologics across therapeutic areas: an example from b-cell targeted therapies.
    Cohen M; Morrow T; Penna P
    Am J Manag Care; 2006 Mar; 12(2 Suppl):S24-37; quiz S38. PubMed ID: 16551202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A method classifying biologics for formulary decision making.
    Broder MS; Reissman D
    Manag Care Interface; 2006 Apr; 19(4):30-2. PubMed ID: 16689025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Research and development of drugs and biologic entities.
    Piascik MM
    Am J Hosp Pharm; 1991 Oct; 48(10 Suppl 1):S4-13. PubMed ID: 1772113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weighing the evidence: trends in managed care formulary decision making.
    de Lissovoy G
    J Clin Psychiatry; 2003; 64 Suppl 17():29-32. PubMed ID: 14680425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Managing biotechnology in a network-model health plan: a U.S. private payer perspective.
    Watkins JB; Choudhury SR; Wong E; Sullivan SD
    Health Aff (Millwood); 2006; 25(5):1347-52. PubMed ID: 16966732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of follow-on drugs and indications on the WHO Essential Drug List.
    Cohen J; Cabanilla L; Sosnov J
    J Clin Pharm Ther; 2006 Dec; 31(6):585-92. PubMed ID: 17176363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Foreword: Follow-on Biologics: Implementation Challenges and Opportunities.
    Paradise J
    Seton Hall Law Rev; 2011; 41(2):501-10. PubMed ID: 21739728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hazard identification and risk assessment for biologics targeting the immune system.
    Weir AB
    J Immunotoxicol; 2008 Jan; 5(1):3-10. PubMed ID: 18382852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?
    Alwawi EA; Krulig E; Gordon KB
    Dermatol Ther; 2009; 22(5):431-40. PubMed ID: 19845720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The year's new drugs & biologics - 2008.
    Graul AI; Revel L; Barrionuevo M; Cruces E; Rosa E; Verges C; Lupone B; Diaz N; Castaner R
    Drug News Perspect; 2009; 22(1):7-29. PubMed ID: 19209296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The year's new drugs and biologics--2006.
    Graul AI; Sorbera LA; Bozzo J; Serradell N; Revel L; Prous JR
    Drug News Perspect; 2007; 20(1):17-44. PubMed ID: 17332898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The challenge of follow-on biologics for treatment of multiple sclerosis.
    Reingold SC; Steiner JP; Polman CH; Cohen JA; Freedman MS; Kappos L; Thompson AJ; Wolinsky JS
    Neurology; 2009 Aug; 73(7):552-9. PubMed ID: 19687456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of biotechnology products.
    Tami J; Evens RP
    Pharmacotherapy; 1996; 16(4):527-36. PubMed ID: 8840359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A clinical development paradigm for cancer vaccines and related biologics.
    Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
    J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biologics for inflammatory bowel disease: drug approval and monitoring in the United States.
    Tremaine WJ
    Gastroenterol Clin North Am; 2006 Dec; 35(4):735-41. PubMed ID: 17129810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Missing data issues at the FDA Center for Biologics Evaluation and Research.
    Scott JA; Hsu H
    J Biopharm Stat; 2011 Mar; 21(2):196-201. PubMed ID: 21390996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The challenge of managing the utilization of biologics in an era of evolution and growth.
    Morrow T
    Manag Care Interface; 2004; Suppl A():3-4. PubMed ID: 15198422
    [No Abstract]   [Full Text] [Related]  

  • 20. Development of probiotics as biologic drugs.
    Hoffman FA
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S125-7; discussion S144-51. PubMed ID: 18181717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.